Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...
In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...
Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...
In recent years, CryoEM has enabled scientists to decipher the structures of the fibrils that form various deposits in neurodegenerative disease. They have not only solved disease-specific folding ...
“Bruce had a brilliant career in both academia and industry and left an indelible mark on the Alzheimer’s disease drug development landscape,” noted Robert Vassar, Northwestern University, Chicago ...
Do you know a conference you think we should list? Let us know by sending us an email with the details to
[email protected].
PhD, National University of Singapore Postdoctoral fellow, University of Oxford Postdoctoral fellow, National Institutes of Health ...
Multiple due dates; see announcement.
Member reports the following financial or other potential conflicts of interest: Full time employee for Eli Lilly. Stocks from Abbvie.